Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Abstract Background Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in...

Full description

Bibliographic Details
Main Authors: Maryam Soleimani Dodaran, Simone Borgoni, Emre Sofyalı, Pernette J. Verschure, Stefan Wiemann, Perry D. Moerland, Antoine H. C. van Kampen
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Breast cancer
DNA methylation
Endocrine therapy
Resistance
Survival
T47D
Online Access:http://link.springer.com/article/10.1186/s12885-020-07100-z

Internet

http://link.springer.com/article/10.1186/s12885-020-07100-z

Similar Items